Cytokine Production (IL-6 and TNFa) in Whole Blood Cell Cultures of Patients with Systemic Lupus Erythematosus

References

• Dinarello GA. Interleukin 1 and the pathogenesis of the acute phase response. N Eng J Med 1984; 311: 1413–8
   PubMed Web of Science ®Google Scholar
• Dinarello GA, Mier JW. Current concepts - lymphokines. N Eng J Med 1987; 317: 940–5
   PubMed Web of Science ®Google Scholar
• Dinarello GA, Cannon JG, Wolff SM. New concepts in the pathogenesis of fever. Rev Infect Dis 1988; 10: 168–89
   PubMedGoogle Scholar
• Dinarello GA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433–50
   PubMed Web of Science ®Google Scholar
• Pepys MB. C reactive protein: the role of an ancient protein in modern rheumatology. Clin Exp Rheumatol 1983; 1: 3–7
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Devogelaer J-P, Van Damme J, Nagant De Deuxchaisnes C, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–8
   PubMed Web of Science ®Google Scholar
• Becker GJ, Waldburger M, Hughes G RV, Pepys MB. Value of serum C reactive protein measurement in the investigations of fever in systemic lupus erythematosus. Ann Rheum Dis 1980; 39: 50–2
   PubMed Web of Science ®Google Scholar
• Swaak A JG, Van Rooyen A, Aarden LA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int 1989; 8: 263–8
   PubMed Web of Science ®Google Scholar
• Meyer C, Huysen V, Smeenk R TJ, Swaak A JG. Profiles of cytokines (TNF and IL-6) and acute phase proteins (CRP and alAG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993; 2: 359–66
   PubMedGoogle Scholar
• Maury C PJ. Monitoring the acute phase response: comparison of tumor necrosis factor (cachectin) and C reactive protein responses in inflammatory and infectious diseases. J Clin Pathol 1989; 43: 1078–82
   Google Scholar
• Maury C PJ, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146–50
   PubMedGoogle Scholar
• Mitamura K, Kang H, Tomita Y, Hashimoto H, Sawada S, Horie T. Impaired tumour necrosis factor-tx (TNFa) production and abnormal B-cell response to TNF in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1991; 85: 386–91
   PubMed Web of Science ®Google Scholar
• Jacob CD, McDevitt HD. Tumor necrosis factor-a in murine autoimmune “lupus” nephritis. Nature 1988; 331: 356–8
   PubMed Web of Science ®Google Scholar
• Malavé I, Searles RP, Montano J, Williams RC. Production of tumor necrosis factor (cachectin) by peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1989; 89: 355–61
   PubMedGoogle Scholar
• Nerad JL, Griffiths JK, Van Der Meer J WM, et al. Interleukin-1-β (IL-l-β), IL-1 receptorantagonist, and TNFa production in whole blood. J Leukoc Biol 1992; 52: 687–92
   PubMed Web of Science ®Google Scholar
• Bloemena E, Roos M TL, Van Heyst J LAM, Vossen J MJJ, Schellekens P TA. Whole blood lymphocyte cultures. J Immunol Methods 1989; 122: 161–7
   PubMedGoogle Scholar
• De Forge LE, Kenney JS, Jones ML, Warren JS, Remick DG. Biphasic production of IL-8 in lipopolysaccharide (LPS) stimulated human whole blood. J Immunol 1992; 148: 2133–41
   PubMedGoogle Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
   PubMed Web of Science ®Google Scholar
• Van Kooten C, Rensink I, Pascual-Salcedo D, Van Oers R, Aarden LA. Monokine production by human T-cells; IL-1 a production restricted to memory T-cells. J Immunol 1991; 146: 2654–8
   PubMed Web of Science ®Google Scholar
• Aarden LA, Helle M, De Groot ER, Brakenhoff J PJ. Relation between hybridoma factor and IL-1. Mechanisms of B-cell neoplasma, F Mecchers, M Potter. Springer, Berlin, Heidelberg, New York 1989; 101–5
   Google Scholar
• Brakenhoff J PJ, De Groot ER, Evers RF, Pannekoek H, Aarden LA. Molecular cloning and expression of hybridoma growth factor in E-coli. J Immunol 1987; 139: 4116–21
   PubMed Web of Science ®Google Scholar
• Helle M, Boeije L, De Groot ER, De Vos A, Aarden LA. Sensitive ELISA for interleukin 6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991; 138: 42–56
   Google Scholar
• Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS. Cytokine response by monocyte/macrophages to free and lipoprotein bound lipopolysaccharide. Infect Immun 1990; 58: 2375–82
   PubMedGoogle Scholar
• Ocklind G. Stimulation of human lymphocytes by phytohem-agglutinin (PHA) in a new ultra-microtest plate. Immunobiology 1986; 171: 339–44
   PubMedGoogle Scholar
• De Groote D, Zangerle PF, Gevaert Y, et al. Direct stimulation of cytokines (IL-lβ, TNFα, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. Comparison with isolated PBMC stimulation. Cytokine 1992; 4: 239–48
   PubMed Web of Science ®Google Scholar
• Elsässer-Beile U, Van Kleist S, Stähle W, Schurhammer-Fuhrmann C, Schulte Mónting J, Gallata H. Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and Basal cell carcinoma. Cancer 1993; 71: 231–6
   PubMed Web of Science ®Google Scholar
• Jacob CD, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HD. Heritable major histocompatibility complex class II associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233–7
   PubMed Web of Science ®Google Scholar
• Malavec I, Searles RP, Montano J, Williams RC. Production of tumor necrosis factor/cachectin by peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1989; 89: 355–61
   PubMedGoogle Scholar
• Segal R, Dayan M, Zinger H, Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation. Clin Exp Immunol 1995; 101: 66–72
   PubMed Web of Science ®Google Scholar
• Prud'homme GJ, Kano DH, Theofilopoulos AN. Quanatitative polymerase chain reaction analysis reveals marked over expression of interleukin-1 beta, interleukin –1 and interferon gamma MRNA in the lymphnodes of lupus-prone mice. Mol Immunol 1995; 32: 495–503
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M, Deans R. Dysregulated lymphokine production in systemic lupus erythromatosus (SLE). Ann N Y Acad Sci 1991; 567–9
   Google Scholar
• Elsasser-Beile U, Kubina R, Gallati H, Schulte Monting J, Van Kleist S. Cytokine production in whole blood cell cultures of patients with Rheumatoid arthritis and collagnosis. Int J Immunopathol Pharmacol 1995; 8: 1–8
   Google Scholar
• Takemura H, Suzuki H, Yoshizaki K. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in sera of patients with systemic sclerosis. Arthritis Rheum 1992; 35: 940–3
   PubMedGoogle Scholar
• Hansen MB, Svenson M, Diamant M, Brendtzen K. Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 1991; 33: 777–81
   PubMed Web of Science ®Google Scholar